Kingsview Wealth Management LLC Sells 1,872 Shares of Gilead Sciences, Inc. $GILD

Kingsview Wealth Management LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,379 shares of the biopharmaceutical company’s stock after selling 1,872 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Gilead Sciences were worth $4,588,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares in the last quarter. Nuveen LLC acquired a new position in shares of Gilead Sciences during the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth about $238,083,000. Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after buying an additional 1,942,433 shares during the period. Finally, Mackenzie Financial Corp grew its stake in shares of Gilead Sciences by 345.7% in the 1st quarter. Mackenzie Financial Corp now owns 2,500,209 shares of the biopharmaceutical company’s stock valued at $280,148,000 after buying an additional 1,939,273 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Wolfe Research upped their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Daiwa Capital Markets upped their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Finally, Argus boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.13.

Gilead Sciences Price Performance

GILD opened at $124.09 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $127.68. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market capitalization of $153.96 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 0.81 and a beta of 0.32. The firm’s fifty day moving average price is $117.61 and its two-hundred day moving average price is $113.02.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the firm earned $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 94,646 shares of company stock valued at $11,311,286. Insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.